Please assess the completion status of the following clinical trial:

Trial Title: On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old~* Male (or transgender) having sex with men~* Not infected with HIV-1 or HIV-2~* Elevated risk of HIV contamination : anal sexual relations with at least 2 different sexual partners within the past 6 months without the systematic use of a condom~* Satisfactory kidney function with a clearance of more than 60 mL/min (Cockcroft formula)~* Alanine aminotransferase (ALT) \< 2.5 Upper Limit of Normal (ULN),~* Neutrophil granulocytes ≥ 1 000/mm3, haemoglobin ≥ 10 g/dL, platelets ≥ 150 000/mm3~* Negative HBs antigen and negative hepatitis C virus (HCV) serology (or negative HCV PCR if positive serology)~* Agrees to be contacted personally, if possible by telephone, short message system (SMS) or e-mail~* Agrees to the constraints imposed by the trial (visits every 2 months)~* Subjects enrolled in or a beneficiary of a Social Security program (State Medical Aid or Aide médicale de l'Etat (AME) is not a Social Security program).~* Signature of the informed consent form.~Exclusion Criteria:~* Subject in a stable and exclusive relationship with a person~* Systematic use of a condom during sexual relations~* Expected to go abroad for more than 3 consecutive months or move expected to a city where the study is not being conducted.~* Presence of significant glycosuria or proteinuria \> 1+ in the urine dipstick, in the absence of infection.~* Presence of significant haematuria or leukocyturia \> 2+ in the urine dipstick, in the absence of infection.~* History of chronic kidney disease, osteoporosis, osteopaenia~* History of pathological bone fracture not related to trauma~* Treatment with Interferon, Interleukin, or antiretrovirals~* Treatment that could inhibit or compete with the tubular secretion of antiretrovirals~* Treatment undergoing investigation~* Intravenous toxicomania~* Subject who is currently receiving or going to receive a potentially nephrotoxic treatment (long-term anti-inflammatory)~* Gastro-intestinal disease (or chronic nausea or vomiting) disrupting the absorption of treatments~* Positive HBs antigen~* Positive HCV serology with positive HCV PCR~* Life-threatening disease (lymphoma) or other serious disease (cardiovascular, renal, pulmonary, unstable diabetes) that could require treatment that could disrupt adherence to the treatment~* Subject potentially non-compliant.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Truvada (Type: ACTIVE_COMPARATOR): associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)
- Placebo of Truvada (Type: PLACEBO_COMPARATOR): associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)

Based on this trial design, predict the completion outcome and termination type (if applicable).